Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

BACKGROUND: MEK is activated in ∼40% colorectal cancer (CRC) and 20–30% non-small cell lung cancer (NSCLC). Selumetinib is a selective inhibitor of MEK1/2, which is currently in clinical development. METHODS: We evaluated the effects of selumetinib in vitro and in vivo in CRC and NSCLC cell lines to...

Descripción completa

Detalles Bibliográficos
Autores principales: Troiani, T, Vecchione, L, Martinelli, E, Capasso, A, Costantino, S, Ciuffreda, L P, Morgillo, F, Vitagliano, D, D'Aiuto, E, De Palma, R, Tejpar, S, Van Cutsem, E, De Lorenzi, M, Caraglia, M, Berrino, L, Ciardiello, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349172/
https://www.ncbi.nlm.nih.gov/pubmed/22569000
http://dx.doi.org/10.1038/bjc.2012.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349172/
https://www.ncbi.nlm.nih.gov/pubmed/22569000
http://dx.doi.org/10.1038/bjc.2012.129

Ejemplares similares